 <h1>Peptic Relief Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>bismuth subsalicylate</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about bismuth subsalicylate. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Peptic Relief.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bismuth subsalicylate: oral suspension, oral tablet, oral tablet chewable</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bismuth subsalicylate (the active ingredient contained in Peptic Relief) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking bismuth subsalicylate:</p><p>In some patients bismuth subsalicylate may cause dark tongue and/or grayish black stools. This is only temporary and will go away when you Stop taking bismuth subsalicylate.</p><ul>
<li>Anxiety</li>
<li>any loss of hearing</li>
<li>confusion</li>
<li>constipation (severe)</li>
<li>diarrhea (severe or continuing)</li>
<li>difficulty in speaking or slurred speech</li>
<li>dizziness or lightheadedness </li>
<li>drowsiness (severe)</li>
<li> fast or deep breathing</li>
<li>headache (severe or continuing) </li>
<li>increased sweating</li>
<li>increased thirst</li>
<li>mental depression</li>
<li> muscle spasms (especially of face, neck, and back)</li>
<li> muscle weakness</li>
<li>nausea or vomiting (severe or continuing) </li>
<li>ringing or buzzing in ears (continuing)</li>
<li>stomach pain (severe or continuing)</li>
<li> trembling</li>
<li>uncontrollable flapping movements of the hands (especially in elderly patients) or other uncontrolled body movements </li>
<li>vision problems</li>
</ul><p>
<!-- end oral suspension, oral tablet, oral tablet chewable --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bismuth subsalicylate: compounding powder, oral suspension, oral tablet, oral tablet chewable</i></p><h3>Nervous system</h3><p><b>Rare</b> (less than 0.1%): Myoclonic encephalopathy </p>
<p><b>Frequency not reported</b>: Weakness, fatigue, depression, anxiety, irritability, insomnia, unsteady gait, motor incoordination, loss of memory, jerky movements, mental confusion, disorientation, difficulty in walking and speaking, tremor, myoclonic jerks, incontinence<sup>[Ref]</sup></p><p>Nervous system toxicity is a common feature of bismuth toxicity.  Bismuth toxicity is characterized by the insidious onset of weakness and fatigue, depression, anxiety, irritability, insomnia, unsteady gait, motor incoordination, loss of memory, and jerky movements.  Acute toxicity may result in the development of mental confusion, disorientation, difficulty in walking and speaking, tremor, myoclonic jerks, and incontinence.</p>
<p></p>
<p>Myoclonic encephalopathy has occurred in patients who have ingested bismuth for several months to years, but the incidence is very rare.  Recovery of patients from bismuth encephalopathy may take several months following discontinuation of use.  Bismuth encephalopathy has generally been reported in patients ingesting salts other than subsalicylate.<sup>[Ref]</sup></p><h3>Other</h3><p>Salicylism has been reported in patients who chronically ingest bismuth subsalicylate (the active ingredient contained in Peptic Relief)   Common complaints include vertigo, diminished hearing, lethargy, CNS dysfunction, confusion, tinnitus, vomiting, and abdominal pain.  Patients may present with respiratory alkalosis and metabolic acidosis, azotemia, and hypoprothrombinemia and platelet dysfunction.  The elderly may be particularly vulnerable to the development of salicylism.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Salicylism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Black stool</p>
<p><b>Common</b> (1% to 10%): Black tongue</p>
<p><b>Frequency not reported</b>: Nausea, vomiting<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Salicylate in pepto-bismol." Med Lett Drugs Ther 22 (1980): 63</p><p id="ref_2">2. Supino-Viterbo V, Sicard C, Risvegliato M, Rancurel G, Buge A "Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patients." J Neurol Neurosurg Psychiatry 40 (1977): 748-52</p><p id="ref_3">3. Weller MP "Neuropsychiatric symptoms following bismuth intoxication." Postgrad Med J 64 (1988): 308-10</p><p id="ref_4">4. Gorbach SL "Bismuth therapy in gastrointestinal diseases." Gastroenterology 99 (1990): 863-75</p><p id="ref_5">5. DuPont HL "Bismuth subsalicylate in the treatment and prevention of diarrheal disease." Drug Intell Clin Pharm 21 (1987): 687-93</p><p id="ref_6">6. Malfertheiner P "Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment." Scand J Gastroenterol Suppl 196 (1993): 34-7</p><p id="ref_7">7. Dipalma JR "Bismuth toxicity." Am Fam Physician 38 (1988): 244-6</p><p id="ref_8">8. Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982): 167</p><p id="ref_9">9. Jungreis AC, Schaumburg HH "Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol)." Neurology 43 (1993): 1265</p><p id="ref_10">10. Bierer DW "Bismuth subsalicylate: history, chemistry, and safety." Rev Infect Dis 12 Suppl 1 (1990): s3-8</p><p id="ref_11">11. Bradley B, Singleton M, Po AL "Bismuth toxicity--a reassessment." J Clin Pharm Ther 14 (1989): 423-41</p><p id="ref_12">12. Gordon MF, Abrams RI, Rubin DB, Barr WB, Correa DD "Bismuth toxicity." Neurology 44 (1994): 2418</p><p id="ref_13">13. Molina JA, Calandre L, Bermejo F "Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters." Acta Neurol Scand 79 (1989): 200-3</p><p id="ref_14">14. Vernace MA, Bellucci AG, Wilkes BM "Chronic salicylate toxicity due to consumption of over-the-counter bismuth subsalicylate." Am J Med 97 (1994): 308-9</p><p id="ref_15">15. Sainsbury SJ "Fatal salicylate toxicity from bismuth subsalicylate." West J Med 155 (1991): 637-9</p><p id="ref_16">16. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Peptic Relief (bismuth subsalicylate)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: antidiarrheals</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Pepto-Bismol, Kaopectate, Bismatrol, Bismatrol Maximum Strength, ... +6 more</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Traveler's Diarrhea</li>
<li>Diarrhea</li>
<li>Diarrhea, Chronic</li>
<li>Helicobacter Pylori Infection</li>
<li>Indigestion</li>
<li>Lymphocytic Colitis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bismuth subsalicylate: compounding powder, oral suspension, oral tablet, oral tablet chewable</i></p><h3>Nervous system</h3><p><b>Rare</b> (less than 0.1%): Myoclonic encephalopathy </p><p><b>Frequency not reported</b>: Weakness, fatigue, depression, anxiety, irritability, insomnia, unsteady gait, motor incoordination, loss of memory, jerky movements, mental confusion, disorientation, difficulty in walking and speaking, tremor, myoclonic jerks, incontinence<sup>[Ref]</sup></p><p>Nervous system toxicity is a common feature of bismuth toxicity.  Bismuth toxicity is characterized by the insidious onset of weakness and fatigue, depression, anxiety, irritability, insomnia, unsteady gait, motor incoordination, loss of memory, and jerky movements.  Acute toxicity may result in the development of mental confusion, disorientation, difficulty in walking and speaking, tremor, myoclonic jerks, and incontinence.</p><p></p><p>Myoclonic encephalopathy has occurred in patients who have ingested bismuth for several months to years, but the incidence is very rare.  Recovery of patients from bismuth encephalopathy may take several months following discontinuation of use.  Bismuth encephalopathy has generally been reported in patients ingesting salts other than subsalicylate.<sup>[Ref]</sup></p><h3>Other</h3><p>Salicylism has been reported in patients who chronically ingest bismuth subsalicylate (the active ingredient contained in Peptic Relief)   Common complaints include vertigo, diminished hearing, lethargy, CNS dysfunction, confusion, tinnitus, vomiting, and abdominal pain.  Patients may present with respiratory alkalosis and metabolic acidosis, azotemia, and hypoprothrombinemia and platelet dysfunction.  The elderly may be particularly vulnerable to the development of salicylism.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Salicylism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Black stool</p><p><b>Common</b> (1% to 10%): Black tongue</p><p><b>Frequency not reported</b>: Nausea, vomiting<sup>[Ref]</sup></p><p id="ref_1">1. "Salicylate in pepto-bismol." Med Lett Drugs Ther 22 (1980): 63</p><p id="ref_2">2. Supino-Viterbo V, Sicard C, Risvegliato M, Rancurel G, Buge A "Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patients." J Neurol Neurosurg Psychiatry 40 (1977): 748-52</p><p id="ref_3">3. Weller MP "Neuropsychiatric symptoms following bismuth intoxication." Postgrad Med J 64 (1988): 308-10</p><p id="ref_4">4. Gorbach SL "Bismuth therapy in gastrointestinal diseases." Gastroenterology 99 (1990): 863-75</p><p id="ref_5">5. DuPont HL "Bismuth subsalicylate in the treatment and prevention of diarrheal disease." Drug Intell Clin Pharm 21 (1987): 687-93</p><p id="ref_6">6. Malfertheiner P "Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment." Scand J Gastroenterol Suppl 196 (1993): 34-7</p><p id="ref_7">7. Dipalma JR "Bismuth toxicity." Am Fam Physician 38 (1988): 244-6</p><p id="ref_8">8. Hasking GJ, Duggan JM "Encephalopathy from bismuth subsalicylate." Med J Aust 2 (1982): 167</p><p id="ref_9">9. Jungreis AC, Schaumburg HH "Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol)." Neurology 43 (1993): 1265</p><p id="ref_10">10. Bierer DW "Bismuth subsalicylate: history, chemistry, and safety." Rev Infect Dis 12 Suppl 1 (1990): s3-8</p><p id="ref_11">11. Bradley B, Singleton M, Po AL "Bismuth toxicity--a reassessment." J Clin Pharm Ther 14 (1989): 423-41</p><p id="ref_12">12. Gordon MF, Abrams RI, Rubin DB, Barr WB, Correa DD "Bismuth toxicity." Neurology 44 (1994): 2418</p><p id="ref_13">13. Molina JA, Calandre L, Bermejo F "Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters." Acta Neurol Scand 79 (1989): 200-3</p><p id="ref_14">14. Vernace MA, Bellucci AG, Wilkes BM "Chronic salicylate toxicity due to consumption of over-the-counter bismuth subsalicylate." Am J Med 97 (1994): 308-9</p><p id="ref_15">15. Sainsbury SJ "Fatal salicylate toxicity from bismuth subsalicylate." West J Med 155 (1991): 637-9</p><p id="ref_16">16. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Peptic Relief (bismuth subsalicylate)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: antidiarrheals</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Traveler's Diarrhea</li>
<li>Diarrhea</li>
<li>Diarrhea, Chronic</li>
<li>Helicobacter Pylori Infection</li>
<li>Indigestion</li>
<li>Lymphocytic Colitis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>